David A. Jett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David A. Jett has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Christina M. Wilhelm
Battelle, 505 King Avenue, JM-7, Columbus, OH 43201-2693, USA
2 shared publications - David T. Yeung
Department of Health and Human Services, National Institute of Allergy and Infectious Diseases/NIH, Bethesda, MD 20892
2 shared publications - Gennady E. Platoff
National Institutes of Health/National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
2 shared publications - Michael C. Babin
Battelle, 505 King Avenue, JM-7, Columbus, OH 43201-2693, USA
2 shared publications Shardell M. Spriggs
National Institute of Neurological Disorders and Stroke, National Institutes of Health, United States
2 shared publicationsA.T. Eldefrawi
Department of Pharmacology & Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, MD USA
1 shared publication
Latest Publications
- Open Access
- 9 October 2024
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 44 (41)
Symposium: What Does the Microbiome Tell Us about Prevention and Treatment of AD/ADRD?
Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRDs) are broad-impact multifactorial neurodegenerative diseases. Their complexity presents unique challenges for developing effective therapies. This review highlights research presented at the 2024 Society for Neuroscience meeting which emphasized the gut microbiome's role in AD pathogenesis by influencing brain function and neurodegeneration through the microbiota–gut–brain axis. This emerging evidence underscores the potential for targeting the gut microbiota to treat AD/ADRD.
- 9 October 2024
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 44 (41)
Open AccessSymposium: What Does the Microbiome Tell Us about Prevention and Treatment of AD/ADRD?
Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRDs) are broad-impact multifactorial neurodegenerative diseases. Their complexity presents unique challenges for developing effective therapies. This review highlights research presented at the 2024 Society for Neuroscience meeting which emphasized the gut microbiome's role in AD pathogenesis by influencing brain function and neurodegeneration through the microbiota–gut–brain axis. This emerging evidence underscores the potential for targeting the gut microbiota to treat AD/ADRD.
- 5 August 2020
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 50 (6) , 474-490
A national toxicology program systematic review of the evidence for long-term effects after acute exposure to sarin nerve agent
Sarin is a highly toxic nerve agent that was developed for chemical warfare during World War II and is used in present conflicts. Immediate effects of acute sarin exposure are established; however, whether effects persist after initial signs have subsided is debated. The National Toxicology Program (NTP) conducted a systematic review to evaluate the evidence for long-term neurological effects following acute (known to be a neurological hazard to humans in the period following exposure up to 7 days and suspected to be a hazard week to years after exposure, given a lower level of evidence in later time periods. Effects included reduced cholinesterase, visual and ocular effects, impaired learning and memory, and altered nervous system morphology. Further mechanistic, targeted animal studies, translational research, and rapid research responses after human exposures may reduce uncertainties on long-term consequences of sarin.
- 5 August 2020
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 50 (6) , 474-490
A national toxicology program systematic review of the evidence for long-term effects after acute exposure to sarin nerve agent
Sarin is a highly toxic nerve agent that was developed for chemical warfare during World War II and is used in present conflicts. Immediate effects of acute sarin exposure are established; however, whether effects persist after initial signs have subsided is debated. The National Toxicology Program (NTP) conducted a systematic review to evaluate the evidence for long-term neurological effects following acute (known to be a neurological hazard to humans in the period following exposure up to 7 days and suspected to be a hazard week to years after exposure, given a lower level of evidence in later time periods. Effects included reduced cholinesterase, visual and ocular effects, impaired learning and memory, and altered nervous system morphology. Further mechanistic, targeted animal studies, translational research, and rapid research responses after human exposures may reduce uncertainties on long-term consequences of sarin.
- Open Access
- 1 January 2020
- Published by Elsevier in Neurobiology of Disease
- Vol. 133, 104557
Preface: Discovery and development of better medical countermeasures for chemical threats targeting the nervous system
- 1 January 2020
- Published by Elsevier in Neurobiology of Disease
- Vol. 133, 104557
Open AccessPreface: Discovery and development of better medical countermeasures for chemical threats targeting the nervous system
- Open Access
- 1 January 2020
- Published by Elsevier in Neurobiology of Disease
- Vol. 133, 104335
Translational research on chemical nerve agents
- 1 January 2020
- Published by Elsevier in Neurobiology of Disease
- Vol. 133, 104335
Open AccessTranslational research on chemical nerve agents
- 2 October 2019
- Published by Taylor & Francis in Toxicology Mechanisms and Methods
- Vol. 31 (4) , 242-243
Civilian research on chemical medical countermeasures
(2019). Civilian research on chemical medical countermeasures. Toxicology Mechanisms and Methods. Ahead of Print.
- 2 October 2019
- Published by Taylor & Francis in Toxicology Mechanisms and Methods
- Vol. 31 (4) , 242-243
Civilian research on chemical medical countermeasures
(2019). Civilian research on chemical medical countermeasures. Toxicology Mechanisms and Methods. Ahead of Print.
- 1 January 2018
- Published by American Chemical Society (ACS)
- p. 83-96
Finding Better Therapeutics for Chemical Poisonings
- 1 January 2018
- Published by American Chemical Society (ACS)
- p. 83-96
Finding Better Therapeutics for Chemical Poisonings
- 1 June 2016
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1374 (1) , 5-9
The NIH Countermeasures Against Chemical Threats Program: overview and special challenges
Intentional exposures to toxic chemicals can stem from terrorist attacks, such as the release of sarin in the Tokyo subway system in 1995, as well as from toxic industrial accidents that are much more common. Developing effective medical interventions is a critical component of the overall strategy to overcome the challenges of chemical emergencies. These challenges include the rapid and lethal mode of action of many toxic chemicals that require equally fast‐acting therapies, the large number of chemicals that are considered threats, and the diverse demographics and vulnerabilities of those who may be affected. In addition, there may be long‐term deleterious effects in survivors of a chemical exposure. Several U.S. federal agencies are invested in efforts to improve preparedness and response capabilities during and after chemical emergencies. For example, the National Institutes of Health (NIH) Countermeasures Against Chemical Threats (CounterACT) Program supports investigators who are developing therapeutics to reduce mortality and morbidity from chemical exposures. The program awards grants to individual laboratories and includes contract resource facilities and interagency agreements with Department of Defense laboratories. The range of high‐quality research within the NIH CounterACT Program network is discussed.
- 1 June 2016
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1374 (1) , 5-9
The NIH Countermeasures Against Chemical Threats Program: overview and special challenges
Intentional exposures to toxic chemicals can stem from terrorist attacks, such as the release of sarin in the Tokyo subway system in 1995, as well as from toxic industrial accidents that are much more common. Developing effective medical interventions is a critical component of the overall strategy to overcome the challenges of chemical emergencies. These challenges include the rapid and lethal mode of action of many toxic chemicals that require equally fast‐acting therapies, the large number of chemicals that are considered threats, and the diverse demographics and vulnerabilities of those who may be affected. In addition, there may be long‐term deleterious effects in survivors of a chemical exposure. Several U.S. federal agencies are invested in efforts to improve preparedness and response capabilities during and after chemical emergencies. For example, the National Institutes of Health (NIH) Countermeasures Against Chemical Threats (CounterACT) Program supports investigators who are developing therapeutics to reduce mortality and morbidity from chemical exposures. The program awards grants to individual laboratories and includes contract resource facilities and interagency agreements with Department of Defense laboratories. The range of high‐quality research within the NIH CounterACT Program network is discussed.
- Open Access
- 1 December 2014
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 281 (3) , 254-265
A comprehensive evaluation of the efficacy of leading oxime therapies in guinea pigs exposed to organophosphorus chemical warfare agents or pesticides
- 1 December 2014
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 281 (3) , 254-265
Open AccessA comprehensive evaluation of the efficacy of leading oxime therapies in guinea pigs exposed to organophosphorus chemical warfare agents or pesticides